(NASDAQ: GANX) Gain Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.13%.
Gain Therapeutics's earnings in 2026 is -$21,239,773.On average, 7 Wall Street analysts forecast GANX's earnings for 2026 to be -$25,174,413, with the lowest GANX earnings forecast at -$27,170,622, and the highest GANX earnings forecast at -$22,841,237. On average, 7 Wall Street analysts forecast GANX's earnings for 2027 to be -$33,291,477, with the lowest GANX earnings forecast at -$56,431,292, and the highest GANX earnings forecast at -$21,497,635.
In 2028, GANX is forecast to generate -$35,326,074 in earnings, with the lowest earnings forecast at -$39,459,251 and the highest earnings forecast at -$30,454,983.